Effect of buprenorphine on CYP3A activity in rat and human liver microsomes

Life Sciences

Volumn 66, Issue 14, 2000, Pages 1293-1298

  Ibrahim, Rami B ^a   Wilson, Jacquelyn G ^a   Thorsby, Mary E ^a   Edwards, David J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Benzodiazepines; Buprenorphine; CYP3A; CYP3A inhibition

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CYTOCHROME P450 3A; DIAZEPAM; KETOCONAZOLE; OPIATE AGONIST; TESTOSTERONE DERIVATIVE;

ANIMAL CELL; ARTICLE; CENTRAL NERVOUS SYSTEM DEPRESSION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER MICROSOME; NEUROTOXICITY; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; BUPRENORPHINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; ENZYME INHIBITORS; HUMANS; HYDROXYTESTOSTERONES; KETOCONAZOLE; MALE; MICROSOMES, LIVER; NARCOTICS; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, SPRAGUE-DAWLEY; SPECTROPHOTOMETRY, ULTRAVIOLET;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0034712305     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(00)00436-7     Document Type: Article

References (23)

1. R.C. Heel, R.N. Brogden, T.M. Speight and G.S. Avery, Drugs 17 81-110 (1979).
2. S.L. Walsh, K.L. Preston, M.L. Stitzer, E.J. Cone and G.E. Bigelow, Clin. Pharmacol. Ther. 55 569-80 (1994).
3. R.E. Johnson, J.H. Jaffe and P.J. Fudala, Jama. 267 2750-2755 (1992).
4. N.K. Mallo, J.H. Mendelson and J.C. Kuehnle, J.Pharmacol.Exp.Ther. 233 31-40 (1982).
5. M. Reynaud, G. Petit, D. Potard and P. Courty, Presse Med. 26 1337-1338 (1998).
6. A. Tracqui, P. Kintz and B. Ludes, J.Anal.Toxicol. 22 430-434 (1998).
7. A. Tracqui, C. Tournoud, F. Flesch, P. Kintz, M. Deveaux, M.H. Ghysel, P. Marquet, G. Pepin, G. Petit, A. Jaeger and B. Ludes, Presse Med. 27 557-561 (1998).
8. P.N. Jain and S.C. Shah, Anesthesia 48 898-899 (1993).
9. J.F. Schmidt, B. Chraemmer-Jorgensen, J.E. Pederson and A. Risbo, Anesthesia 40 583-586 (1985).
10. J.T. Knape, Anesthesiology 64 382-384 (1986).
11. D. Touzeau and L. Courrier, Ann.Med.Interne. 145 (Suppl.3):19-22 (1994).
12. K.Z. Preston, S.R. Griffiths, M.L. Stitzer, G.E. Bigelow and I.A. Liebson, Clin.Pharmacol.Ther. 36 534-41 (1984).
13. D.R. Abernethy, D.J. Greenblatt, D.S. Morse and R.I. Shader, Br.J.Clin.Pharmacol. 19 (1) 51-7 (1985).
14. K.E. Thummel and G.R. Wilkinson, Annu.Rev.Pharmacol. 38 389-430 (1998).
15. C. Iribarne, D. Picart, P. Dreano, J.-P. Bail and F. Berthou, Life Sci. 60 1953-1964 (1997).
16. D.J. Edwards, F.H. Bellevue III and P.M. Woster, Drug Metab.Dispos. 24 1287-1290 (1996).
17. D.J. Edwards and S.M. Bernier, Life Sci. 59 1025-1030 (1996).
18. S.K. Teoh, J.H. Mendelson, N.K. Mello, J. Kuehnle, S. Pradit and E.M. Rhoades, Psychopharmacol. 13 87-99 (1993).
19. W.K. Bickel, M.L. Stitzer, G.E. Bigelow, I.A. Liebson, D.R. Jasinski and R.E. Johnson, J.Pharmacol.Exp.Ther. 247 47-53 (1988).
20. J.C. Gorski, D.R. Jones, B.D. Haehner-Daniels, M.A. Hamman, E.M. O'Mara and S.D. Hall SD, Clin.Pharmacol.Ther. 64 133-143 (1998).
21. K.T. Olkkola, J.T. Backman and P.J. Neuvonen, Clin.Pharmacol.Ther. 55 481-485 (1994).
22. A. Varhe, K.T. Olkkola and P.J. Neuvonen, Clin.Pharmacol.Ther. 56 601-607 (1994).
23. J.J. Kuhlman, S. Lalani, J.J. Magluilo, B. Levine, W.D. Darwin, R.E. Johnson and E.J. Cone, J.Anal.Toxicol. 20 369-378 (1996).